Eugenol / AntiAg Cancer Research Results

Eug, Eugenol: Click to Expand ⟱
Features:

Eugenol — Eugenol is a naturally occurring phenylpropanoid and volatile aromatic phenol most strongly associated with clove oil from Syzygium aromaticum. Eugenol is a phenolic aromatic ingredient that is chiefly derived from clove oil. It is formally classified as a small-molecule phytochemical, essential-oil constituent, food-flavouring agent, and experimental anticancer adjunct rather than an approved oncology drug. Standard abbreviations include EUG and 4-allyl-2-methoxyphenol. It is also present in cinnamon, basil, bay, nutmeg, and other aromatic plants. The oncology evidence is mainly preclinical, with strongest support for apoptosis induction, PI3K/Akt suppression, anti-metastatic effects, and chemo/radiosensitization in cell and animal models. clove oil has been advertised as a dental pain-relieving agent and germicide, and is used in mouthwashes and pharmaceutical drugs. Eugenol (4-allyl (-2-mthoxyphenol)), a phenolic natural compound available in honey and in the essential oils of different spices such as Syzgium aromaticum (clove), Pimenta racemosa (bay leaves), and Cinnamomum verum (cinnamon leaf).
-eugenol is the major ingredient of three spices (i.e. clove, cinnamon,and nutmeg)
-clear to pale yellow liquid with an oily consistency and a spicy aroma. It is sparingly soluble in water and well soluble in organic solvents.
-entering the systemic circulation within 30-60 minutes, paradoxically limits it therapeutic effectiveness.

Primary mechanisms (ranked):

  1. Induction of intrinsic and extrinsic apoptosis through mitochondrial dysfunction, Bax/Bcl-2 shift, cytochrome-c release, caspase activation, and PARP cleavage.
  2. Suppression of PI3K/Akt/mTOR and related survival signalling, including FOXO3a-linked autophagy/apoptosis in breast cancer models.
  3. Anti-inflammatory transcriptional modulation, especially ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling, and context-dependent STAT3/IL-6 axis suppression.
  4. Anti-metastatic and anti-invasive activity through ↓ MMP-2/MMP-9, ↓ migration, ↓ invasion, and reduced epithelial-mesenchymal transition markers in selected models.
  5. Anti-angiogenic effects through ↓ VEGF-linked signalling and reduced invasion/angiogenesis markers in gastric and other cancer models.
  6. ROS redox modulation with model-dependent pro-oxidant stress in cancer cells and antioxidant/anti-inflammatory effects in non-malignant contexts.
  7. Chemosensitization and radiosensitization, reported preclinically with cisplatin, gemcitabine, and ionizing radiation, but not clinically established.

Bioavailability / PK relevance: Eugenol is rapidly absorbed and extensively metabolized, mainly through conjugation pathways, so systemic exposure is transient and formulation-dependent. Its volatility, lipophilicity, rapid metabolism, and local irritation risk make delivery strategy important. Nanoemulsions, encapsulation, and conjugated delivery systems are being explored preclinically to improve stability, exposure, and tumour delivery.

In-vitro vs systemic exposure relevance: Many in-vitro anticancer studies use micromolar-to-high-micromolar concentrations that may exceed freely achievable systemic exposure after ordinary dietary or flavouring-level intake. Low-dose mechanistic reports exist in some breast cancer models, but translation remains uncertain. Essential-oil or clove-derived exposure should not be equated with purified eugenol pharmacology because source composition, dose, and route strongly affect exposure.

Clinical evidence status: Preclinical. Eugenol has cell-line and animal-model anticancer evidence, plus limited adjunctive clinical-context use in aromatherapy or topical/dental products, but there is no established clinical evidence supporting eugenol as a cancer treatment. Registry-visible oncology studies involving essential oils generally assess symptom support or mixtures, not purified eugenol as an anticancer therapeutic.

Eugenol Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis and caspases ↑ Bax, ↑ cytochrome-c, ↑ caspase-3/8/9, ↓ Bcl-2, ↓ PARP integrity Mixed; cytoprotection at low exposure but irritation/cytotoxicity at high exposure R/G Apoptotic tumour-cell killing Core and most reproducible anticancer axis across breast, cervical, gastric, lung, and other models.
2 PI3K Akt mTOR survival signalling ↓ PI3K/Akt, ↓ mTOR signalling, ↑ FOXO3a activity, ↑ autophagy/apoptosis Context-dependent R/G Reduced survival signalling and increased treatment vulnerability Highly relevant in breast cancer and lung cancer models; may overlap with HER2/PI3K-Akt effects.
3 NF-κB COX-2 inflammatory signalling ↓ NF-κB, ↓ COX-2, ↓ inflammatory cytokine signalling ↓ inflammatory signalling in non-malignant inflammatory contexts R/G Anti-inflammatory and anti-survival transcriptional pressure Important bridge between anticancer and general anti-inflammatory pharmacology.
4 MMP invasion and metastasis ↓ MMP-2, ↓ MMP-9, ↓ migration, ↓ invasion Context-dependent G Anti-invasive and anti-metastatic activity Mechanistically meaningful for breast, fibrosarcoma, gastric, and lung cancer models.
5 Angiogenesis and VEGF-linked signalling ↓ VEGF-linked angiogenic markers, ↓ invasion-associated vascular support Context-dependent; excessive exposure may irritate tissues G Reduced tumour vascularization support Best supported in animal carcinogenesis and metastasis-associated models rather than clinical oncology.
6 Cell cycle arrest ↑ p21, ↑ p27, ↓ cyclin-linked proliferation, S-phase or G2/M effects depending on model Context-dependent G Reduced proliferation Secondary but common contributor to antiproliferative activity.
7 Mitochondrial ROS redox stress ↑ ROS or redox stress in some cancer models; antioxidant effects in others Often ↓ oxidative stress at low exposure; irritation or toxicity possible at high exposure P/R/G Context-dependent redox modulation Do not tag simply as antioxidant. Cancer-cell effect can be pro-oxidant, antioxidant, or mixed depending on dose, timing, and model.
8 NRF2 antioxidant response Mixed or context-dependent; not a primary anticancer-defining axis Potential ↑ cytoprotective antioxidant response in non-malignant stress models G Secondary redox adaptation Include only as secondary/contextual unless a specific study demonstrates NRF2-dependent cancer-cell modulation.
9 Glycolysis and metabolic reprogramming Metabolomic shifts reported; likely ↓ proliferative metabolic fitness in selected CRC/oral cancer contexts Unclear G Metabolic stress Mechanistically interesting but less mature than apoptosis, PI3K/Akt, and invasion axes.
10 Chemosensitization ↑ cisplatin cytotoxicity, ↑ gemcitabine activity, ↑ apoptosis Potential normal-cell toxicity not adequately defined R/G Adjunctive treatment sensitization Preclinical only; promising but insufficient for clinical-use claims.
11 Radiosensitization ↑ ionizing-radiation cytotoxicity in cervical and oral cancer models Normal-tissue protection versus sensitization remains unresolved R/G Radiation response enhancement Preclinical only; should be tagged as experimental radiosensitizer, not clinically validated.
12 Clinical Translation Constraint In-vitro exposure may exceed realistic free systemic levels High-dose clove oil/eugenol can irritate mucosa and has overdose hepatotoxicity risk G Limits direct translation Major constraints are rapid metabolism, dose-limited tolerability, formulation dependence, lack of oncology trials, and distinction between food-level GRAS use and therapeutic dosing.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
AntiAg, Antiplatelet aggregation: Click to Expand ⟱
Source:
Type:
Antiplatelet aggregation refers to the process by which platelets clump together to form a blood clot.
The plethora of evidence indicates that among multiple hemostasis components, platelets play major roles in cancer progression by providing surface and granular contents for several interactions as well as behaving like immune cells.On the other hand, there are suggestions that antiplatelet treatment may promote solid tumor development in a phenomenon described as “cancers follow bleeding.” The controversies around antiplatelet agents justify insight into the subject to establish what, if any, role platelet-directed therapy has in the continuum of anticancer management.
The interplay between antiplatelet aggregation and cancer is an area of active research, with potential implications for therapeutic strategies. Antiplatelet agents, such as aspirin, are being investigated for their role in cancer prevention and treatment, particularly in reducing metastasis and improving patient outcomes.
Scientific Papers found: Click to Expand⟱
7146- AL,  GI,  Eug,  CAP,    Herbal remedies and anticoagulant therapy
- Review, Nor, NA
*AntiAg↑, The allicin derivative of garlic root has been shown to enhance fibrinolytic activity and inhibit platelet aggregation in patients with coronary artery disease
*PGE2↓, Other herbs may also affect platelet function through inhibition of prostaglandin metabolism. Ginger, used by pregnant women for the relief of nausea and vomiting
*AntiAg↑, while clove – a common kitchen spice and important source of dietary antioxidants (60), contains two antiplatelet components (eugenol and acetyl eugenol) which inhibit platelet thromboxane formation and increase formation of 12-HPETE
*TXA2↓,
*AntiAg↑, Red pepper (capsaicin), an herb used to alleviate diabetic neuropathy (74), inhibits both platelet aggregation and release (75), as well enhancing fibrinolytic activity

6381- Eug,    Biological Properties and Prospects for the Application of Eugenol—A Review
- Review, Var, NA
*eff↑, Isoeugenol derivatives have become a popular subject of research due to their fungicidal and insecticidal properties, because they exhibit greater antimicrobial activity than eugenol
*BioAv↝, Eugenol is a clear to pale yellow liquid with an oily consistency and a spicy aroma. It is sparingly soluble in water and well soluble in organic solvents.
*BioAv↝, Eugenol has low chemical stability and is sensitive to oxidation and various chemical interactions. When orally administered, it is rapidly absorbed by various organs and metabolized in the liver.
*BioAv↑, encapsulation of eugenol seems to be the best solution to prevent early absorption, improve its water solubility, and, thus, increase its activity. eugenol delivered increases at least sixfold in infected cells when delivered as solid lipid NPs
*antiOx↑, Eugenol has demonstrated various antioxidant, analgesic, antimutagenic, anti-platelet, antiallergic, anti-swelling, and anti-inflammatory properties.
*AntiAg↑,
*Inflam↓,
*AntiBio↑, It has also displayed antimicrobial effects against many human pathogens, including a wide group of Gram-positive and Gram-negative bacteria and fungi and a number of parasites
*MAOA↓, Eugenol is a popular antioxidant and monoamine oxidase (MAO) inhibitor, and it is also known to exhibit neuroprotective properties
*neuroP↑,
*ROS↓, Eugenol is known to scavenge free radicals, inhibit the generation of reactive oxygen species, prevent the production of reactive forms of nitrogen
*RNS↓,
*eff↑, The study on eugenol showed that this compound has synergistic activity with various antibiotics, such as vancomycin, penicillin, ampicillin, and erythromycin, and the combination of these compounds allowed a reduction in MIC values of 5–1000 times
NF-kB↓, killing cancer cells. The molecular mechanism is believed to include various stages: inhibiting NF-κB activation, downregulating prostaglandin synthesis, reducing cyclooxygenase-2 activity,
PGE2↓,
COX2↓,
TumCCA↑, inducing cell cycle arrest in the S phase, and causing apoptotic cell death by lowering inflammatory cytokine levels
Apoptosis↑,
TumCMig↓, even a low dose of eugenol interfered with the migration and invasion of carcinogenic cells, inhibited lung cancer cell viability,
TumCI↓,
tumCV↓,
PI3K↓, blocking the PI3K/Akt pathway (an intracellular signaling pathway involved in cell cycle regulation) and inhibiting MMP (matrix metalloproteinase) activity
Akt↓,
MMPs↓,
ChemoSen↑, eugenol is believed to enhance the inhibition of breast cancer stem cells by cisplatin by inhibiting the activity of aldehyde dehydrogenases (ALDH)
ALDH↓,
*Pain↓, Eugenol is a popular painkiller and anesthetic used in dental practice.
*VGSC↓, It has been found to inhibit voltage-gated sodium channels (VGSC) in the primary supply neurons of the teeth in various studies, including one based on a rat model
*IL1β↓, It is also known to be an inhibitor of pro-inflammatory mediators, including IL-1β and IL-6, tumor necrosis factor alpha (TNF-α), prostaglandin E2 (PGE2), expression of inducible oxide nitrate synthase (iNOS)
*IL6↓,
*TNF-α↓,
*iNOS↓,
*5LO↓, nuclear factor kappa B (NF-κB), and leukotriene C4 and 5-lipoxygenase (5-LOX)
*chemoPv↑, eugenol dimers have shown chemopreventive properties by inhibiting cytokine expression in macrophages


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   PI3K↓, 1,  

Migration(tgid=13) ⓘ

MMPs↓, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   NF-kB↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   RNS↓, 1,   ROS↓, 1,  

Cell Death(tgid=5) ⓘ

iNOS↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

VGSC↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 4,  

Angiogenesis & Vasculature(tgid=14) ⓘ

TXA2↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   Inflam↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

MAOA↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 2,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   neuroP↑, 1,   Pain↓, 1,  
Total Targets: 22

Scientific Paper Hit Count for: AntiAg, Antiplatelet aggregation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:399  Target#:10  State#:%  Dir#:%
  wNotes=on  sortOrder:rid,rpid

 

Home Page